Gland Pharma (GLAND) Share Price Falls 2.04%: What Drove Today’s Move
- September 16, 2026
- Posted by: Harsh Piplani
- Category: News
Gland Pharma Share Price fell today, with the stock trading at Rs 2,821.80, down 2.04% from the previous close of Rs 2,880.45. The company’s market capitalisation stands at Rs 48,214.81 Cr, placing it in the Large Cap category. This Gland Pharma Share Price update matters because the session was lower across the full day’s range, yet the verified data does not establish a company-specific catalyst. For readers tracking Gland Pharma Stock News, the session is best understood through the exact price move, valuation profile, and healthcare sector context. Univest is presenting the move using only verified market data so that the Gland Pharma Share Price story remains factual, current and comparable with peers.
In today’s Gland Pharma Share Price Today action, the stock opened at Rs 2,872.90, touched an intraday high of Rs 2,912.20 and a low of Rs 2,795.00 before ending at Rs 2,821.80. That places the share price below the open, below the previous close and near the lower part of the day’s range. The turnover was Rs 23.06 Cr. Since the supplied data confirms the price event but does not establish a company-specific trigger, the focus shifts to what the numbers show about valuation, fundamentals and sector positioning in Gland Pharma Stock News.
Gland Pharma (GLAND) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,821.8 |
| Previous Close | Rs 2,880.45 |
| Today's Move | -Rs 58.65 (-2.04%) |
| Open | Rs 2,872.9 |
| High | Rs 2,912.2 |
| Low | Rs 2,795 |
| Turnover | Rs 23.06 crore |
| Market Capitalisation | Rs 48,214.81 crore |
| Market Cap Category | Large Cap |
Gland Pharma Share Price Today reflected a same-day decline of Rs 58.65, or 2.04%, from the previous close of Rs 2,880.45 to Rs 2,821.80. The day began at Rs 2,872.90, which was below the previous close, and the stock briefly moved to Rs 2,912.20 before slipping to an intraday low of Rs 2,795.00. That leaves the session with a narrow trading band relative to the day’s movement, and the closing price finished closer to the low than the high.
For readers following Gland Pharma Share Price Live, the main factual takeaways are the exact open, high, low, close and turnover. The turnover of Rs 23.06 Cr is a verified traded-value figure and should be read as such. It is not a standalone explanation for the move. The company is a Large Cap, with market capitalisation of Rs 48,214.81 Cr, so today’s Gland Pharma Share Price Fall is a notable single-session event within a large listed company. The next lens is how this session fits into the company’s financial and valuation profile.
Gland Pharma (GLAND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 48,214.81 crore |
| P/E Ratio | 42.11x |
| P/B Ratio | 4.47x |
| ROE | 10.56% |
| ROCE | 14.96% |
| EPS | Rs 68.41 |
| Book Value Per Share | Rs 644.34 |
| Dividend Yield | 0.69% |
These numbers place the Gland Pharma Share Price story in a valuation-first frame rather than a growth-story frame. The stock’s P/E of 42.11 is above the same-industry median of 31.74 and also below the peer-set average of 47.98, while P/B of 4.47 is slightly above the industry median of 3.02 and close to the industry average of 4.44. ROE at 10.56% is below the industry median of 11.78%, and ROCE at 14.96% is above the industry median and average of 13.65%. Univest uses these verified ratios to help readers interpret Gland Pharma Stock News without guessing at the day’s trigger.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 42.11x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 4.47x |
| Benchmark Median P/B | 3.02x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 10.56% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 11.19% |
| Company ROCE | 14.96% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.65% |
| Company Market Capitalisation | Rs 48,214.81 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
| Benchmark Average Market Cap | Rs 14,144.11 crore |
Gland Pharma operates in Healthcare, within the Pharmaceuticals & Drugs industry. The supplied benchmark scope covers the same industry and includes 200 companies, allowing a useful comparison for Gland Pharma Share Price against a broader peer set. Within that universe, the company’s P/E of 42.11 sits above the benchmark median of 31.74 but below the benchmark average of 47.98. Its P/B of 4.47 is above the benchmark median of 3.02 and close to the benchmark average of 4.44. ROE at 10.56% is slightly below the industry median of 11.78%, while ROCE at 14.96% is above the median and average of 13.65%.
The market-cap statistics provide additional sector context. The industry median market capitalisation is Rs 750.50 Cr, while the average is Rs 14,144.11 Cr. Against that backdrop, Gland Pharma’s market capitalisation of Rs 48,214.81 Cr places it well above both median and average industry size. The sector frame also matters for Gland Pharma Share Price Today because the same industry includes companies with very different valuation and profitability profiles. The company’s current multiples are neither isolated nor extreme in the context of the sector, and the day’s decline should therefore be read alongside these exact benchmark values rather than any unsupported narrative.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
Peer comparison helps position Gland Pharma Share Price within a visible set of listed healthcare names. At a P/E of 42.11, Gland Pharma is below Torrent Pharmaceuticals at 84.58 and Divi’s Laboratories at 83.41, but above Sun Pharmaceutical Industries at 36.40, Cipla at 32.62, Zydus Lifesciences at 24.29 and Dr. Reddy’s Laboratories at 29.78. This means the stock sits in the middle of the supplied peer range on earnings multiples.
On profitability ratios, Gland Pharma’s ROE of 10.56% is below Sun Pharma at 14.85%, Divi’s at 16.19%, Torrent Pharma at 26.76%, Zydus at 19.69% and Cipla at 11.83%, while remaining above Aurobindo Pharma at 9.93% from the wider industry list. Its ROCE of 14.96% is above Cipla at 16.00%? No, Cipla stands at 16.00%, so Gland Pharma is slightly below Cipla but above Dr. Reddy’s at 13.75% and Aurobindo at 12.76%. On size, Gland Pharma’s Rs 48,214.81 Cr market cap is materially smaller than Sun Pharma, Divi’s, Torrent and the other large peers in the supplied comparison set.
Why Investors Are Watching Gland Pharma
- Gland Pharma Share Price fell 2.04% today to Rs 2,821.80 from Rs 2,880.45.
- The stock moved between Rs 2,795.00 and Rs 2,912.20 in the session.
- Market capitalisation stands at Rs 48,214.81 Cr and the company is classified as Large Cap.
- P/E is 42.11, P/B is 4.47, ROE is 10.56%, and ROCE is 14.96%.
- Within the same industry, the benchmark scope covers 200 companies, and Gland Pharma Share Price sits above the median P/E and P/B levels.
About Gland Pharma
Gland Pharma operates in Healthcare and is part of the Pharmaceuticals & Drugs industry. That classification is the main verified business context supplied for this Gland Pharma Share Price article. Investors tracking Gland Pharma Stock News often use the company’s current market capitalisation, valuation ratios and industry comparison to understand where the stock stands in the broader healthcare universe. The verified data for Gland Pharma Share Price Today therefore centres on listed-market metrics rather than any broader operating narrative.
Track Gland Pharma Share Price on Univest
Use Gland Pharma (GLAND) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Univest allows readers to track Gland Pharma Share Price, Gland Pharma Share Price Today, key ratios, shareholding pattern, 52-week levels and market insights in one place. You can also review Gland Pharma Stock News, Gland Pharma Stock Analysis and Gland Pharma Fundamental Analysis alongside live price updates on Univest.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Gland Pharma Share Price fall today?
Ans. Gland Pharma Share Price fell 2.04% to Rs 2,821.80 from Rs 2,880.45. The supplied data confirms the price event, but it does not establish a company-specific catalyst for the move.
What was Gland Pharma Share Price Today’s closing price?
Ans. Gland Pharma Share Price Today closed at Rs 2,821.80. The stock opened at Rs 2,872.90, hit a high of Rs 2,912.20 and a low of Rs 2,795.00 during the session.
What is Gland Pharma’s market capitalisation?
Ans. Gland Pharma’s market capitalisation is Rs 48,214.81 Cr. The company is classified as Large Cap, which provides size context for Gland Pharma Share Price and its current valuation profile. The company operates in the Healthcare sector.
What are the key valuation metrics for Gland Pharma Share Price?
Ans. Gland Pharma Share Price is supported by a P/E ratio of 42.11 and a P/B ratio of 4.47. EPS is Rs 68.41, book value is Rs 644.34, and dividend yield is 0.69%.
How does Gland Pharma compare with healthcare peers?
Ans. In the supplied peer set, Gland Pharma’s P/E of 42.11 is below Torrent Pharma and Divi’s but above Sun Pharma, Cipla, Zydus Lifesciences and Dr. Reddy’s. Its ROE is 10.56%.
What does the sector benchmark show for Gland Pharma Share Price?
Ans. The same-industry benchmark covers 200 companies. Gland Pharma’s P/E of 42.11 is above the median of 31.74, while its P/B of 4.47 is close to the industry average of 4.44.
What does Gland Pharma’s profitability profile show?
Ans. Gland Pharma reports ROE of 10.56% and ROCE of 14.96%. Those figures show return generation in exact terms and can be compared with the same-industry median of 11.78% ROE and 13.65% ROCE.
